Hanall Biopharma Co., Ltd.

KOSE:A009420 Stock Report

Market Cap: ₩2.0t

Hanall Biopharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Seungwon Jeong

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.8yrs
CEO ownershipn/a
Management average tenure1.8yrs
Board average tenure4yrs

Recent management updates

Recent updates

Risks Still Elevated At These Prices As Hanall Biopharma Co., Ltd. (KRX:009420) Shares Dive 30%

Dec 09
Risks Still Elevated At These Prices As Hanall Biopharma Co., Ltd. (KRX:009420) Shares Dive 30%

Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up

Oct 14
Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up

Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)

Jun 26
Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)

Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely

May 22
Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely

There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Mar 13
There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

Feb 12
Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Jan 25
What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Jan 04
Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Dec 14
Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

Nov 21
Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

CEO

Seungwon Jeong

1.8yrs

Tenure

Sean Jeong, also known as Seungwon, M.D., MBA, serves as President & Director at Hanall Biopharma Co.,Ltd since 2021 and is its Co-Chief Executive Officer since April 2023 and was its Chief Executive Offic...

Leadership Team

NamePositionTenureCompensationOwnership
Sean Jeong
President1.8yrsno datano data
Su-Jin Park
Co-CEO, VP & Director1.8yrsno data0.0037%
₩ 75.4m
Christopher Slavinsky
Chief Business Development & Legal Officerless than a yearno datano data
Nam-Yong Cho
Senior Executive Director of Sales & Marketing and Senior Managing Directorno datano datano data

1.8yrs

Average Tenure

Experienced Management: A009420's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Sean Jeong
President4yrsno datano data
Su-Jin Park
Co-CEO, VP & Director1.8yrsno data0.0037%
₩ 75.4m
Sung-Hou Kim
Member of Scientific Advisory Boardno datano datano data
Seung-Kook Park
Directorno datano data0.16%
₩ 3.4b
Jae-Ho Cheong
Member of Scientific Advisory Boardno datano datano data
Yong Choi
Member of Scientific Advisory Boardno datano datano data
Aekyung Kim
Member of Scientific Advisory Boardno datano datano data
Young Shin
Member of Scientific Advisory Boardno datano datano data
Jason Song
Member of Scientific Advisory Boardno datano datano data
Jae-chun Yoon
Chairmanno datano datano data
Hun Jung
Independent Director4yrsno datano data

4.0yrs

Average Tenure

Experienced Board: A009420's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 06:10
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hanall Biopharma Co., Ltd. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ka-hye HongDaishin Securities Co. Ltd.
Jonghyun ParkDAOL Investment & Securities Co., Ltd.
null nullDBS Bank Ltd